Transformative advances in medical technology rarely occur in isolation, but rather may be indirectly informed, if not accelerated, by advances in related fields. Bonhoeffer et al introduced the first transcatheter valve in 2000, implanting it in a 12 year-old boy with tetralogy of Fallot 1 .
The report of the transcatheter aortic valve by Cribier a mere two years later suggests the interdependence of investigators on breakthroughs in related fields 2 . The advancements in cardiac devices are shared among pediatric and adult cardiologists, with benefits ideally befalling both patient populations when a breakthrough occurs, whether that technology was initially introduced for adults or children.
It is notable that the Melody valve implanted in 2015 is in large part the same device and delivery system as the first transcatheter valve implanted in 2000. The operator learning curve has been significant, while the device has remained for the most part unmodified. The unchanging character of the valve speaks to two issues specifically.
When considering the performance and clinical of a bioprosthetic valve, one might subscribe to the British surgeon Dr. Donald Ross's approach: the primary consideration is the early safety and efficacy of the valve, with secondary value placed on valve durability 3 . In consideration of early safety and efficacy, the Melody valve has shown excellent results. As has been demonstrated in multiple studies, a significant learning curve occurred to optimize patient safety during transcatheter valve implantation -such as careful coronary artery assessment, prestenting the outflow tract, and anticipation of outflow tract tearing 4, 5 . It is worth remembering that some of the experiences on this technical learning curve are embedded within the results of Early efficacy has also been previously demonstrated in a wide range of reports that speak to the immediate improvements in hemodynamics, the early improvement in patients' delivery system as the first transcatheter valve implanted in 2000. The operator l lea ea earn rn rnin in ing g g cu cu curv rv rve e e has been significant, while the device has remained for the most part unmodified. The unch h han an angi gi ging ng ng c c char ra ract c c er of the valve speaks to two o i i iss ss ssu ues specifically.
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Clearly the FDA intends, rather, for future device development to occur through trials, and the Humanitarian Device Exemption (HDE) pathway makes sponsoring a pediatric device trial somewhat more attractive. It is notable that the Melody valve is one of only six pediatric cardiac devices to attain HDE approval since HDE introduction in 1997. The aim of the HDE pathway is to incentivize industry to manufacture devices for areas of unmet clinical need 24 . The HDE allows a regulatory pathway, and yet the economic burden from device manufacturers and from hospitals remains significant. HDE approval is based on studies demonstrating both safety and "probable benefit" of the device (compared to normal post-market approval (PMA) in which studies establish both safety and effectiveness) 25 . Unfortunately, payors are free to resist reimbursement of devices lacking efficacy data. Future device trials for pediatric populations may indeed follow the same HDE route to attain FDA-approval. But the success of the HDE pathway will be measured by the number of devices put forward on this track for FDA approval.
Thus, in 2015 the congenital heart disease community continues to lag behind the adult cardiac world, where advancements and modifications can be more quickly studied and implemented. We are currently enjoying an incredibly active and productive era of incredibly clever cardiac device development. The current study demonstrates the value of transcatheter valve implantation for treatment of congenital heart disease. One hopes that the Melody valve, despite its incredible success and durability, becomes the first of many transcatheter options for children with valve failure.
Conflict of Interest Disclosures:
None.
from hospitals remains significant. HDE approval is based on studies demonstrat t tin in ing g g bo bo both th th s s saf af afet e e y and "probable benefit" of the device (compared to normal post-market approval (PMA) in which tud die ie ies s s es es esta ta tabl bl blish h bo bo both safety and effectiveness) 25 . . U U Unfortunately, payor rs rs ar a a e free to resist e e eim m mbursement t o o of dev ev evic ic ices es es l l lac ac acki ki king ng g e e eff ff ffic ic ica acy da d d t t ta. F Fu u utur r re e e de de devi vi vice ce c t tri r r al al als s fo fo for p pedi di diat at at i ri ric c c po po popu u ul l lati ti tion on ons s s ma ma may y y in i i deed d f f fol o o lo o ow w w the e e s sa s me e H H HDE D D r r ro o out t te t to a at atta a ain F FDA DA DA-a a app pp ppr r rova va val. . Bu Bu But t t th h he su ucc cc cces e e s of of of t t the H H HDE pa pa path th thwa a way wi i will ll ll b b be e e me me meas as asur r ured ed ed b b by th th the e e nu n numb mb mber er er o o of f f de de devi i vice ce ces s s p p put t ut f f for or orwa a ward rd rd o o on n n th th this is is t t tra ra rack ck ck f f for or or F F FDA DA DA a a app pp ppro ro rova a val l l. Clinical an an and d d hemodynam mi mic c ou ou ut tc t om om ome es e u u up p p to to to 7 7 7 y yea ea e rs a a aft f f e e er tra an n nscat at athe he hete te ter r r pu ulm lm lmon on onar ar ary y y v valv v ve e e re repl pl plac ac acem em men n nt t t in in in t t the u us u m m melody valve in nves s stigatio o on n nal device e e e exemp mp mption n t t tr rial l. Ci Ci Cir r rcu u ulat tio ion. 20 0 015 5;131 31 31:XX-X--X XX X X. X. Ta Tayl l ylor or or A A AM M M. P P Phy h hysi si siol ol olog og ogi i ica ca cal l l co co cons ns nseq eq eque e uenc nc nces es es o o of f f pe pe perc rc rcut t utan an aneo eo eous s us p p pul l ulmo mo mona na nary ry ry y
